$CGEM News

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Cullinan Therapeutics To Host An Immunology Day Event in New York City For Analysts And Institutional Investors On June 10

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

The FDA Grants Orphan Drug Designation To Cullinan Therapeutics' CLN-049 For Relapsed/Refractory Acute Myeloid Leukemia

BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $38 Price Target

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Cullinan Therapeutics To Reveal Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $37

Cullinan Therapeutics (NASDAQ:CGEM) Posts Narrower Q1 Loss, Eyes Key Clinical Data Catalysts

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Cullinan Therapeutics Q1 EPS $(0.75) Beats $(0.87) Estimate

BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $38 Price Target

Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst

HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $30

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Cullinan Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

Taiho, Cullinan Announce Zipalertinib NDA Accepted By FDA For NSCLC Harboring EGFR ex20ins Mutations; PDUFA Date Set Feb. 27, 2027

Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data

Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $36

Cullinan Therapeutics: Q4 Earnings Insights